Purpose To derive a health state classification system (HSCS) from the cancer-specific quality of life questionnaire, the EORTC QLQ-C30, as the basis for a multi-attribute utility instrument. Methods The conceptual model for the HSCS was based on the established domain structure of the QLQ-C30. Several criteria were considered to select a subset of dimensions and items for the HSCS. Expert opinion and patient input informed a priori selection of key dimensions.
Introduction
The European Organisation for Research and Treatment of Cancer (EORTC) has a modular approach to the assessment of health-related quality of life (HRQOL) [1] . Their core questionnaire, the QLQ-C30 [2] , is one of the most widely used patient-reported outcome measures in cancer clinical trials. The scoring algorithm produces 15 scales [3] : five key aspects of functioning; a range of symptoms commonly experienced by cancer patients; and a global assessment of HRQOL. In this way, the QLQ-C30 provides a comprehensive profile of outcomes that are important to patients and their healthcare providers. However, because the QLQ-C30 is a HRQOL profile measure, not a preference-based measure, it cannot be used in cost-utility analysis (CUA) [4] .
CUA is now required or preferred in many jurisdictions for health technology assessment and health reimbursement decisions [5] [6] [7] [8] . CUA is a cost-effectiveness analysis that uses a health outcome metric called utility to weight survival, typically as the Quality-Adjusted Life Year (QALY). The utility metric has three key features that distinguish it from the scales of the QLQ-C30 and other HRQOL profile measures. First, key dimensions of HRQOL are integrated into a single index. Second, it is interpreted as a cardinal scale with two key anchor points: 1 is equivalent to full health (the maximum possible value) and 0 is equivalent to being dead (health states worse than death have negative values) [4] . Third, obtaining utilities requires stated preference-based assessment methods, or valuation tasks [9] , i.e. standard gamble [10] , time trade-off [11] or discrete choice experiments [12, 13] . These tasks typically pose implicit or explicit trade-offs between dimensions of HRQOL and survival, which are the empirical basis of the weighting of HRQOL dimensions in the utility index.
Some preference-based measures have been derived from HRQOL profile measures [14] [15] [16] [17] , typically in two stages. First, a subset of dimensions and items is selected from the HRQOL measure to form a health state classification system (HSCS). This is required because non-preference-based HRQOL measures typically include more items than is manageable in the valuation task required for the second stage, in which a sample of health states is valued and an algorithm derived for estimating the utility of all possible health states. The outputs of these two stages-a HSCS and a utility scoring algorithm-constitute a multi-attribute utility instrument (MAUI). This paper describes the first step in developing an internationally valid, cancer-specific MAUI based on the QLQ-C30. The second step is addressed in a companion paper [18] .
Methods
To derive a HSCS from the QLQ-C30, we adapted and extended methods used previously [17, 19] . This involved determining the core dimensions and then applying nine criteria to select items within dimensions. The rationale and methods for each criterion are described below. The research was conceived and conducted by the Multi-Attribute Utility in Cancer (MAUCa) Consortium, and coordinated from the University of Sydney (Human Research Ethics Committee approval 13207).
The EORTC QLQ-C30 (version 3)
This is a multidimensional questionnaire composed of 30 items which form five functioning scales, three multi-item symptom scales, five single-item symptom scales plus a financial difficulties item and a two-item global HRQOL scale [3] . Its development was informed by extensive literature review, stakeholder input, psychometric evaluation and field testing [1, 2] , and its validity and reliability are well established [2, 20] . The 28 functioning and symptom items are rated on a four-point scale (1 = 'Not at all', 2 = 'A little', 3 = 'Quite a bit', 4 = 'Very much').
Core dimensions of the HSCS: a priori inclusions and exclusions
The authors met in October 2010 to determine the core dimensions of the HSCS. We represent a range of relevant expertise: health economics (JEB, RN, SP, ASP, DR, RV, TAY), HRQOL in cancer (NKA, DFC, PMF, MTK, GV), psychometrics (DSJC, PMF, JFP), behavioural science (MJ, NKA) and oncology (PG, GV). Given the robustness of the QLQ-C30's development process, we agreed that its established domain structure provides a good basis for the conceptual model for the HSCS, but that 15 dimensions (i.e., QLQ-C30's 15 scales) would be unmanageable in subsequent valuation tasks. The two global health/QOL items were excluded because conventionally the attributes in MAUIs are specific domains of health. The Financial Concerns item was excluded as it describes a consequence rather than an aspect of health. Four functioning domains were considered essential-physical, role, emotional and social. Cognitive functioning was deemed non-essential for CUA in cancer and is the least reliable scale [2] , so was recommended for exclusion, pending results from other criteria. We agreed that six common symptoms of cancer (pain, fatigue, nausea/vomiting, gastrointestinal disturbance, appetite loss, sleep disturbance) were likely to be important in CUA in cancer and may provide greater sensitivity (to differences between groups) and responsiveness (to change over time) than generic MAUIs. The remaining symptoms were deemed of lower priority, with decisions about inclusion/exclusion pending results from other criteria. Following dimension selection, we used the quantitative methods described below to guide item selection.
Data
Criteria 1-8 (below) were evaluated via secondary analysis of datasets containing QLQ-C30v3 and patient age, sex, primary cancer site, stage and treatment. Criteria 1-7 required only one observation per patient, and Criteria 8 required two observations per patient. Suitable datasets were sought via MAUCa Consortium members and their associates. Categorical variables were coded as follows:
• Primary cancer site (15 categories) Breast; colorectal; genitourinary; gynaecological; head and neck; leukaemia; hepato-biliary; lung; melanoma; myeloma; gastrooesophageal; prostate; sarcoma; testicular; other.
• Disease stage (2 categories) Loco-regional; recurrent/ metastatic.
• Timing of assessment (3 categories) Either baseline (prior to the start of a course of treatment), on-treatment (during a course of treatment), or follow-up (during clinical follow-up after a course of treatment).
• Treatment (17 categories) No treatment; chemotherapy only; radiotherapy only; hormone therapy only; surgery only; analgesics only; then a further 11 categories for various combinations of those treatments.
Criterion 9 (patient opinion) required primary data collected using a study-specific self-report survey. Cancer patients were recruited from four Australian hospitals: three in regional New South Wales and one in metropolitan Queensland.
Data analysis

Confirmatory factor analysis (CFA)
CFA was used to confirm the QLQ-C30 measurement model prior to selecting items from each factor for the HSCS; technical details are reported elsewhere [21] . Given that the QLQ-C30 items are ordinal, the mean-and variance-adjusted weighted least squares (WLSMV) estimation method was used and implemented with MPlus. Standardised factor loadings were examined. Measurement invariance of the factor structure across primary cancer sites was tested with multi-group CFA, as reported elsewhere [22] . 
Criteria to assess items within dimensions
The aims of Criteria 1-8 were to identify problems with items that might justify exclusion from the HSCS. Criteria 1-5 were assessed with Rasch analysis for each dimension confirmed with CFA and implemented in RUMM2030 [17, 23] . The criteria are summarised below.
1. Fit of items to the Rasch model Overall fit was assessed by examining the Chi-squared statistic with a Bonferroni correction. Misfit due to persons or items ([1.5 the standard deviation of the fit residual) was further assessed via fit residuals for individual items or persons (items with fit residuals [2.5 were removed; persons with fit residuals [2.5 were removed only if they appeared to contribute to item misfit). This process was repeated until only well-fitting items remained and the overall goodness of fit statistic was non-significant. 2. Disordered response thresholds An appropriately functioning item requires a response format that respondents use in a consistent manner. We assessed this by examining item-threshold probability curves. 3. Spread of item thresholds across the latent variable An item with thresholds that cover a wide range of the latent variable is a better single representative of the dimension than an item with thresholds within a narrow range. We inspected the item maps and present each item's lowest and highest response threshold as summary statistics. 4. Differential item function (DIF) A form of bias, in which systematic differences in patterns of responding to an item are observed between individuals with different characteristics, despite having the same level of the latent variable. We examined DIF by sex and cancer site. 5. Local dependence For any pair of items with residual correlation C0.3 above the mean residual correlation for all pairs, we considered forming a composite item for inclusion in the HSCS. 6. Floor and ceiling effects Frequencies of response categories for each item were examined for floor or ceiling effects. Items exhibiting either effect were considered poor candidates for the HSCS, either because they are uncommon and therefore unlikely to affect patients' HRQOL, or because they may be unresponsive to treatments. 7. Sensitivity to differences between early-and late-stage cancer For each item, Cohen's measure of effect size, d, was calculated as the mean of late-stage patients minus the mean of early-stage patients divided by the pooled standard deviation for these two groups.
Responsiveness of items to change due to treatment
Assessing responsiveness requires two observations per patient over a period when HRQOL is expected to change in a systematic way [24] . As clinical context differed markedly across the available datasets, we used change from baseline to on-treatment as the anchor for expected change and calculated responsiveness indices for each study separately as the mean difference between baseline and on-treatment observations divided by baseline standard deviation (effect size [25] ). Datasets were considered suitable for assessing responsiveness if change of at least 0.2SD was observed in at least one HRQOL domain score. 9. Patient opinion We sought cancer patients' opinions about the relative importance of items. We developed a survey, refined iteratively through a series of 'think aloud' interviews with nine patients in a large Australian metropolitan hospital, to ensure that selfcompleting participants understood the cognitive task required [26] . The survey was subsequently administered to 79 patients in four Australian hospitals (one metropolitan, three rural). QLQ-C30 items were presented in five groupings: physical functioning (5 items); emotional functioning (4); role, cognitive and social functioning (6); fatigue, pain, nausea/vomiting (7); dyspnoea, sleep disturbance, appetite loss, constipation, diarrhoea (5). Respondents were instructed to tick the three items in each group that had affected their HRQoL most since their cancer was diagnosed ('Top 3'), and then select the one that had affected their HRQoL most ('Most Important'). We calculated the frequency with which each item was nominated as 'Most Important' and 'Top 3'.
Final decisions after considering all criteria
The authors met in October 2012 to consider results for Criteria 1-8 and to make penultimate decisions on item inclusion/exclusion. During 2013, the patient survey and DCE methods experiment were conducted and their results considered in finalising decisions about the content of the HSCS.
Results
Eighteen suitable datasets were obtained [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . Table 1 summarises their characteristics and the number of observations each contributed to various psychometric analyses.
A pooled dataset of 2616 observations (one per patient) was used for CFA and analyses for Criteria 1-7. All commonly occurring cancers are represented, 40 % with localised/regional and 60 % recurrent/metastatic (Table A, online appendix). All common treatments were represented, with 54 % of observations related to chemotherapy, 30 % to radiotherapy, 27 % to surgery, 4 % to hormone therapy; 65 % related to a single therapy, 26 % to multiple therapies and 9 % to no therapies (Table B , online appendix). In 22 %, HRQOL was assessed prior to therapy (baseline), 44 % during therapy and 33 % during follow-up. For Criterion 8, nine datasets containing a total of 749 patients with both baseline and on-treatment observations were used to estimate responsiveness (Table C, online appendix). Patient illness and treatment characteristics of patients in the Patient Opinion substudy (used to assess Criterion 9) are presented in Table D (online appendix). Table 2 Table D (online) . We describe below how these results informed decisions about which items to retain in the HSCS. Table 3 presents the dimensions and levels in the resultant HSCS.
Confirmatory factor analysis
The loadings of all items on their respective factors were relatively strong and statistically significant (p \ 0.001). Model fit was adequate (CFI = 0.98, TLI = 0.98, RMSEA = 0.071).
Rasch analysis
Within their dimensions, no item exhibited poor fit to the Rasch model or local dependence. One item exhibited a disordered item response threshold and two items exhibited DIF. Thus Criteria 1, 2, 4 and 5 generally played little role in identifying items for exclusion from the HSCS. Table 2 Summary of results for the nine criteria by which items were assessed for suitability to represent their respective dimension within the health classification system of the multi-attribute utility instrument Criteria provided good coverage of the latent construct, as reflected in the range from the lowest response threshold for Item 2 to highest threshold for Item 3. Both items had good sensitivity and responsiveness, and together accounted for the majority of patients' ratings for the 'Top 3' and 'Most Important' items. Items 2 and 3 were therefore chosen as a pair to represent this dimension, with 4 levels defined as in Table 3 .
Role functioning
Rasch model (p = 0.612), item (0.09) and person (1.36) fit were all good. There was little to distinguish the two role functioning items in terms of psychometric criteria: both gave similar coverage of the latent variable, both exhibited DIF by primary cancer site and both had similarly good sensitivity and responsiveness. As Item 6 was commonly chosen as 'Most Important' or 'Top 3' by patients, it was selected to represent this dimension in the HSCS.
Emotional functioning
Rasch model, item and person fit were all good (0.894, 0.86 and 1.19, respectively). These four items provided similar coverage of the latent variable. Although none were particularly sensitive, all but Item 22 had generally good responsiveness. Item 22 (worry) was selected to represent this dimension in the initial valuation task [18] , largely because it was most commonly chosen as 'Most Important' or 'Top 3' by patients. However, after reviewing the results from the valuation task [18] , this decision was changed to Item 24 (depressed), for reasons outlined in the discussion.
Social functioning
Rasch model, item and person fit were all good (0.503, 0.77 and 0.62, respectively). Item 26 (family life) provided a wider range than Item 27 (social activities) and was chosen more often as 'Most Important' or 'Top 3' by patients. To avoid disadvantaging people without family, we combined both items in the HSCS. Among the remaining single-symptom scales of the QLQ-C30, Item 16 (constipation) and 17 (diarrhoea) were selected as a pair to represent bowel problems. Both had good responsiveness and together were chosen quite commonly as 'Most Important' and 'Top 3' by patients. Further, our team of oncologists noted their importance as common symptoms of both cancer and its treatments. Item 11 (trouble sleeping) was very commonly chosen as 'Most Important' and 'Top 3' by patients, so was included. Item 13 (lacked appetite) had good sensitivity and responsiveness, and was considered clinically important by our oncologists.
Discussion
We have conducted extensive analyses using 18 datasets representing 14 countries and all common cancer sites, stages and treatment, to derive a HSCS from the EORTC QLQ-C30. This HSCS is the descriptive part of a cancerspecific MAUI called the QLU-C10D. This name was endorsed by the EORTC QOL Group Executive Committee in April 2014: 'QLU' indicates it is a utility measure; 'C' indicates its origin in the EORTC's core questionnaire; '10D' indicates 10 domains (mobility, role functioning, social functioning, emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems). Note that the QLU-C10D is not a brief-form profile instrument, nor a stand-alone measure, but a utility scoring algorithm for use in trials that use the QLQ-C30. The use of a large international pooled dataset representing a wide range of cancers and treatments, and the inclusion of both oncologist and patient opinion, supports the international applicability and clinical validity of the HSCS. However, it contains more dimensions than previous MAUIs except the 15D [45] . To complete the QLU-C10D's development, we have developed a valid and feasible valuation method to generate a preference-based utility scoring algorithm [18] . Country-specific valuation studies are underway in Australia and Europe, and studies in Canada and USA may follow.
Our work extends that of Rowen et al., [46] , who applied the methods of Young et al. [17] to data from 655 multiple myeloma patients to derive an eight-dimensional HSCS. Our HSCS has the same dimensions plus an addition of two (Sleep and Appetite). Four of these dimensions are identical (Emotional Functioning, Fatigue, Nausea, Bowel Problems), one contains the same items but different levels (Physical Functioning) and three contain different items (Role Functioning, Social Functioning, Pain). Pickard et al. used similar psychometric item selection methods to derive multi-attribute models in their mapping study [19] , obtaining results that had some similarities and some differences from ours and Rowen et al's. These differences in results are likely due to different patient populations and the item selection process itself, which requires judgment to reach a decision across a range of criteria. Given these differences, we recommend the QLU-C10D be used, particularly as it is based on such a broad spectrum of patients and has been endorsed by the EORTC QOL Group.
We adapted and extended the methods of Young et al. [17] in two significant ways. First, we used confirmatory factor analysis, which is more appropriate and efficient than exploratory factor analysis in deriving a HSCS from a HRQOL profile measure with a well-established domain structure [47] . Second, we added an innovative aspect to incorporate patients' opinions. This assisted with the decision-making where candidate items could not be differentiated using statistical methods. Notably, associated qualitative work revealed that it is often difficult for patients to distinguish severity and importance [48] , suggesting that severity is a good proxy for importance in general.
The EORTC QLQ-C30 has been mapped to other preference-based utility measures: the EQ-5D, SF-6D and 15D [49] . As this provides a method to estimate utilities from responses to the QLQ-C30, this raises the question: Is there a need for a MAUI developed directly from the QLQ-C30? A directly derived societal value set for the QLQ-C30 is preferable for several reasons. Mapping enables utilities to be predicted from HRQOL profile scores using datasets containing both the profile measure and a validated utility instrument. However, mapping functions assume that the generic MAUI is appropriate for the target cancer population and sensitive to health changes in it; these assumptions are difficult to test empirically and are rarely tested. Thus utilities may be under-predicted if the generic MAUI is insensitive to change, and changes in symptoms measured by the QLQ-C30 may not be reflected in generic utility values. Further, various mapping functions are used, there is no consensus on which is best, utility values vary greatly, and overall model fit is generally only moderate [49] . The mappings are highly dependent on the dataset(s) from which regressions are estimated and therefore on the coverage of health state space in the patient samples, which are rarely comprehensive. The application of mapping functions which fit the data poorly may result in unrealistic QALY assessments and correspondingly inefficient health resource allocation decisions. Finally, regression generally results in biased estimates [50] ; the highest scores are underestimated and the lowest scores are overestimated, with bias increasing as the correlation between the profile measure and the generic MAUI decreases. This was illustrated empirically in a review of 30 mapping studies that showed predicted values from mapping functions had less variance than the original observed values [51] . All these issues support the need for directly elicited preferences for a HSCS based on QLQ-C30, which is the purpose of the QLU-C10D. Decisionmaking bodies that have considered these issues have placed a lower preference on mapping-based approaches [7, 8] .
This study has some limitations. All datasets were from western or European countries; further work is required to ascertain applicability in other parts of the world. While most common cancers were included, inevitably some cancers were not, e.g. primary brain cancer. The sample for the patient input component was limited to Australians, with few patients with very advanced disease. Item selection required synthesis across a range of criteria; as there were no strict decision rules about how to weight evidence across criteria, whether it be conflicting or confirming, the final decisions required the team's collective judgment.
Using the QLQ-C30 as a basis for a MAUI HSCS could arguably have some shortcomings, because the QLQ-C30 includes a mixture of proximal (symptoms) and distal (the implications of those symptoms for functioning) domains. If dimensions in a MAUI are strongly causally related, this may compromise assumptions of structural independence, create implausible health states (e.g., high fatigue but high role functioning) and induce double counting. Since the QLU-C10D includes both symptoms and their consequences, the degree of a lack of structural independence for this measure may be more extensive than in other preference-based measures.
The decision to exclude cognitive function from the HSCS was based on clinician and patient input about the relative importance of all dimensions, and our empirical analyses suggested other dimensions were more likely to be sensitive to differences across a wide range of clinical contexts. However, a limitation of our study was that our patient samples did not contain patients with primary brain tumours. Further, patients with serious cognitive impairments are likely to be excluded from quality of life assessment in clinical trials generally. Interestingly, the cognitive functioning scores of our samples were only slightly better than those of the EORTC reference values for brain cancer patients [52] . Although cognitive impairment is emerging as an important consequence of cancer and its treatment, current evidence about 'chemo brain' in breast cancer suggests that such impairment tends to be modest [53, 54] . If cognitive functioning is to be given more consideration in health economic decisions, other approaches will be needed.
The development of the QLU-C10D by the MAUCa Consortium represents a significant advance in the incorporation of quality of life information into economic decisions about cancer treatments. Because the QLU-C10D contains symptoms commonly experienced by cancer patients, it may be more sensitive in cancer populations than generic MAUIs, although this will also depend on the values assigned to these symptoms by the general population in valuation studies. Once country-specific value sets are generated, further studies should examine how the utilities generated by this new cancer-specific MAUI compare to those of generic MAUIs. If the QLU-C10D utility scores are correlated with those of generic MAUIs and are at least as sensitive and responsive, respondent burden could be reduced by avoiding the need to use a generic utility measure in trials in addition to the QLQ-C30.
